Ocean Biomedical (NASDAQ: OCEA) is reporting that a broad U.S. patent has been issued to Dr. Jack A. Elias, MD, one of the company’s scientific cofounders. The patent is for bispecific antibodies targeting chitinase 3-like-1 (“CHi3L1”) and programmed cell death protein 1 (“PD-1”). The company called it “a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a ‘master regulator’ of tumor growth in multiple visceral cancers.” According to the announcement, the bispecific antibody is a cutting-edge immunotherapy approach that demonstrates significant potential by combining Ocean’s proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1 in a bispecific-antibody format. The company reports that these bispecific antibodies “have been shown to synergistically kill tumor cells at levels dramatically exceeding the effectiveness of either the anti-CHi3L1 antibody or the anti-PD-1 antibody alone — in multiple cancer types and multiple animal models.”
According to the company, the patent has been granted for a range of cancers, including prostate, colon, rectal, ovarian, kidney, breast, glioblastoma, melanoma and lung. “This bispecific antibody pathway discovery is a monumental leap forward,” said Ocean Biomedical scientific cofounder Dr. Jack A. Elias, MD, in the press release. “By controlling CHi3L1 and concurrently targeting PD-1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways. We believe our discoveries will advance cancer research, and eventually treatment and patient outcomes, forward.”
To view the full press release, visit https://ibn.fm/BsHou
About Ocean Biomedical Inc.
Ocean Biomedical is a Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer and pulmonary fibrosis, as well as the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most. To learn more, visit www.OceanBiomedical.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork